{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T04:06:06Z","timestamp":1778126766153,"version":"3.51.4"},"reference-count":36,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"CAMS Innovation Fund for Medical Sciences","award":["2021-I2M-1-066"],"award-info":[{"award-number":["2021-I2M-1-066"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["SZSM201911006"],"award-info":[{"award-number":["SZSM201911006"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["SZSM202011010"],"award-info":[{"award-number":["SZSM202011010"]}]},{"name":"Sanming Project of Medicine in Shenzhen","award":["2021-I2M-1-066"],"award-info":[{"award-number":["2021-I2M-1-066"]}]},{"name":"Sanming Project of Medicine in Shenzhen","award":["SZSM201911006"],"award-info":[{"award-number":["SZSM201911006"]}]},{"name":"Sanming Project of Medicine in Shenzhen","award":["SZSM202011010"],"award-info":[{"award-number":["SZSM202011010"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Background: Gallbladder cancer (GBC) is a highly aggressive malignancy often diagnosed at an advanced stage due to its asymptomatic onset. Despite surgery being the only potentially curative option, recurrence and poor prognosis remain common, especially in advanced-stage diseases. There is limited consensus regarding the extent of lymphadenectomy, hepatic resection, and the role of adjuvant therapies. Identifying prognostic factors and optimizing treatment strategies are critical for improving outcomes. This multicenter retrospective study was conducted to evaluate the clinical and pathological predictors of survival and recurrence in GBC patients that underwent radical surgery and to assess the potential benefit of adjuvant therapies in advanced stages. Methods: This was a retrospective cohort study of GBC patients who underwent curative-intent resection for GBC between 2010 and 2022 at two tertiary medical centers in China. The baseline characteristics, surgical data, pathology, adjuvant therapy, and follow-up outcomes were analyzed. The survival outcomes were assessed using Kaplan\u2013Meier methods and Cox regression models. Subgroup analyses were conducted to explore the impact of postoperative adjuvant chemotherapy, period of surgical treatment, and extent of resection. Multiple imputation was used to address missing data. Results: The 5-year overall survival (OS) rate was 57.4%. Independent predictors of a poorer OS included CA19-9 &gt; 30 U\/mL (HR = 1.861, p = 0.003), poor\/moderate-to-poor differentiation (HR = 2.134, p = 0.004), T3\u2013T4 stage (HR = 2.685, p = 0.001), N1\u2013N2 stage (HR = 2.217, p = 0.002), M1 stage (HR = 2.308, p = 0.001), and a high CAN score (HR = 1.875, p = 0.009). Adjuvant chemotherapy improved the OS in the stage III\u2013IV patients (24.8 vs. 17.3 months, p = 0.036), though the DFS improvement was not significant (p = 0.133). No survival difference was observed between the segment IVb + V resection and wedge resection in the T2b patients. The patients treated after 2017 had a better OS (p = 0.024), possibly due to improved surgical techniques and perioperative care. Conclusions: Radical surgery remains critical for GBC. Accurate staging and tailored perioperative strategies, including chemotherapy, may improve outcomes, though further prospective studies are needed to validate these findings.<\/jats:p>","DOI":"10.3390\/curroncol32060328","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T03:57:18Z","timestamp":1748923038000},"page":"328","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prognostic Factors and Treatment Outcomes in Gallbladder Cancer Patients Undergoing Curative Surgery: A Multicenter Retrospective Cohort Study"],"prefix":"10.3390","volume":"32","author":[{"given":"Bowen","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Hepatobiliary Surgery, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China"},{"name":"Department of Hepatobiliary Surgery, General Surgery, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250012, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanjiang","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China"},{"name":"Beijing Key Laboratory of Cell and Gene Therapy for Digestive System Cancers, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China"},{"name":"Department of Gastrointestinal Surgery, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing 102218, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianping","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyu","family":"Bi","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianqiang","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China"},{"name":"Beijing Key Laboratory of Cell and Gene Therapy for Digestive System Cancers, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41572-022-00398-y","article-title":"Gallbladder cancer","volume":"8","author":"Roa","year":"2022","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer","volume":"397","author":"Valle","year":"2021","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1016\/j.scib.2024.09.026","article-title":"Burden of biliary tract carcinoma in China (1990-2021): Findings from the 2021 Global Burden of Disease Study","volume":"69","author":"Zhang","year":"2024","journal-title":"Sci. Bull."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1158\/1078-0432.CCR-11-2417","article-title":"Chemokine (C-X-C motif) ligand 12 is associated with gallbladder carcinoma progression and is a novel independent poor prognostic factor","volume":"18","author":"Lee","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"101951","DOI":"10.1016\/j.eclinm.2023.101951","article-title":"Surgical outcomes of gallbladder cancer: The OMEGA retrospective, multicentre, international cohort study","volume":"59","author":"Balakrishnan","year":"2023","journal-title":"EClinicalMedicine"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/bjs.11618","article-title":"Role of tumour location and surgical extent on prognosis in T2 gallbladder cancer: An international multicentre study","volume":"107","author":"Kwon","year":"2020","journal-title":"Br. J. Surg."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1245\/s10434-020-08858-z","article-title":"Extended Resections for Advanced Gallbladder Cancer: Results from a Nationwide Cohort Study","volume":"28","author":"Kuipers","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4342","DOI":"10.1097\/JS9.0000000000001403","article-title":"Prognostic factors for resected cases with gallbladder carcinoma: A systematic review and meta-analysis","volume":"110","author":"Lv","year":"2024","journal-title":"Int. J. Surg."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1186\/s12957-022-02857-y","article-title":"Survival analysis and prognostic factors of the carcinoma of gallbladder","volume":"20","author":"Feroz","year":"2022","journal-title":"World J. Surg. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/jso.25450","article-title":"The optimal number of lymph nodes to evaluate among patients undergoing surgery for gallbladder cancer: Correlating the number of nodes removed with survival in 6531 patients","volume":"119","author":"Tsilimigras","year":"2019","journal-title":"J. Surg. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): A randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S1470-2045(24)00082-2","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): Patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"25","author":"Burris","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","article-title":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): A multicentre, single-arm, phase 2b study","volume":"24","author":"Harding","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1073274820915514","DOI":"10.1177\/1073274820915514","article-title":"Clinicopathological Differences in T2 Gallbladder Cancer According to Tumor Location","volume":"27","author":"Kim","year":"2020","journal-title":"Cancer Control"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"101693","DOI":"10.1016\/j.suronc.2021.101693","article-title":"Comparing survival rate and appropriate surgery methods according to tumor location in T2 gallbladder cancer","volume":"40","author":"Sung","year":"2022","journal-title":"Surg. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1177\/000313481508100623","article-title":"The rationality of resectional surgery and palliative interventions in the management of patients with gallbladder cancer","volume":"81","author":"Ercan","year":"2015","journal-title":"Am. Surg."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Chen, C., Geng, Z., Shen, H., Song, H., Zhao, Y., Zhang, G., Li, W., Ma, L., and Wang, L. (2016). Long-Term Outcomes and Prognostic Factors in Advanced Gallbladder Cancer: Focus on the Advanced T Stage. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0166361"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1016\/j.ejso.2022.06.029","article-title":"Surgery in combination with systemic chemotherapy is associated with improved survival in stage IV gallbladder cancer","volume":"48","author":"Casabianca","year":"2022","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s13193-014-0317-4","article-title":"Chemotherapy and targeted therapy for gall bladder cancer","volume":"5","author":"Sirohi","year":"2014","journal-title":"Indian. J. Surg. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2217\/imt-2022-0191","article-title":"Update on immunotherapy in the management of gallbladder cancer","volume":"15","author":"Kassab","year":"2023","journal-title":"Immunotherapy"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","article-title":"Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): Updated overall survival from a randomised phase 3 study","volume":"9","author":"Oh","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Fang, C., Li, W., Wang, Q., Wang, R., Dong, H., Chen, J., and Chen, Y. (2022). Risk factors and prognosis of liver metastasis in gallbladder cancer patients: A SEER-based study. Front. Surg., 9.","DOI":"10.3389\/fsurg.2022.899896"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00423-023-02924-2","article-title":"Standardized lymph node dissection for gallbladder cancer under laparoscopy: En-bloc resection technique","volume":"408","author":"Cheng","year":"2023","journal-title":"Langenbecks Arch. Surg."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/jso.25825","article-title":"Survival benefit of lymphadenectomy for gallbladder cancer based on the therapeutic index: An analysis of the US extrahepatic biliary malignancy consortium","volume":"121","author":"Sahara","year":"2020","journal-title":"J. Surg. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"7136","DOI":"10.1002\/cam4.4250","article-title":"Effect of lymphadenectomy on the prognosis for N0 gallbladder carcinoma patients: A study based on SEER database","volume":"10","author":"Wu","year":"2021","journal-title":"Cancer Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jss.2020.08.041","article-title":"Gallbladder Cancer Surgery in the United States: Lymphadenectomy Trends and Impact on Survival","volume":"258","author":"Maegawa","year":"2021","journal-title":"J. Surg. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.surg.2020.12.039","article-title":"Hepatectomy strategy for T2 gallbladder cancer between segment IVb and V resection and wedge resection: A propensity score-matched study","volume":"169","author":"Chen","year":"2021","journal-title":"Surgery"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1477-2574.2012.00530.x","article-title":"Molecular prognostic markers in gallbladder carcinoma","volume":"14","author":"Jagannath","year":"2012","journal-title":"HPB"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e249840","DOI":"10.1001\/jamanetworkopen.2024.9840","article-title":"KRAS Allelic Variants in Biliary Tract Cancers","volume":"7","author":"Moffat","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Yoon, S.B., Woo, S.M., Chun, J.W., Kim, D.U., Kim, J., Park, J.K., So, H., Chung, M.J., Cho, I.R., and Heo, J. (2024). The predictive value of PD-L1 expression in response to anti-PD-1\/PD-L1 therapy for biliary tract cancer: A systematic review and meta-analysis. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1321813"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Oh, D.-Y., He, A.R., Qin, S., Chen, L.-T., Okusaka, T., Kim, J.W., Suksombooncharoen, T., Lee, M.A., Kitano, M., and Burris, H.A. (J. Hepatol., 2025). Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study, J. Hepatol., in press.","DOI":"10.1016\/j.jhep.2025.05.003"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S2468-1253(21)00171-0","article-title":"Current and emerging therapies for advanced biliary tract cancers","volume":"6","author":"Kam","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/6\/328\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:46:22Z","timestamp":1760031982000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/6\/328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,3]]},"references-count":36,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["curroncol32060328"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32060328","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,3]]}}}